315 related articles for article (PubMed ID: 15581262)
21. Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study.
Bakken RJ; Paczkowski M; Kramer HP; Axelson AA; Williams DW; Malcolm SK; Sumner CR; Kelsey DK
Curr Med Res Opin; 2008 Feb; 24(2):449-60. PubMed ID: 18179733
[TBL] [Abstract][Full Text] [Related]
22. [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children].
Gaillez C; Sorbara F; Perrin E
Encephale; 2007 Sep; 33(4 Pt 1):621-8. PubMed ID: 18033153
[TBL] [Abstract][Full Text] [Related]
23. Suboptimal dosing of Strattera (atomoxetine) for ADHD patients.
Clemow DB
Postgrad Med; 2014 Sep; 126(5):196-8. PubMed ID: 25420287
[TBL] [Abstract][Full Text] [Related]
24. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder.
Caballero J; Nahata MC
Clin Ther; 2003 Dec; 25(12):3065-83. PubMed ID: 14749146
[TBL] [Abstract][Full Text] [Related]
25. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
Holzer B; Lopes V; Lehman R
J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):415-8. PubMed ID: 23952189
[TBL] [Abstract][Full Text] [Related]
26. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
Reed VA; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill DR; Kryzhanovskaya LA; Savill NC
CNS Drugs; 2016 Jul; 30(7):603-28. PubMed ID: 27290715
[TBL] [Abstract][Full Text] [Related]
27. Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder.
Párraga HC; Párraga MI; Harris DK
Int J Psychiatry Med; 2007; 37(4):415-24. PubMed ID: 18441629
[TBL] [Abstract][Full Text] [Related]
28. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
Spencer T; Heiligenstein JH; Biederman J; Faries DE; Kratochvil CJ; Conners CK; Potter WZ
J Clin Psychiatry; 2002 Dec; 63(12):1140-7. PubMed ID: 12523874
[TBL] [Abstract][Full Text] [Related]
29. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.
Takahashi M; Goto T; Takita Y; Chung SK; Wang Y; Gau SS
Asia Pac Psychiatry; 2014 Mar; 6(1):62-70. PubMed ID: 23857916
[TBL] [Abstract][Full Text] [Related]
30. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
Capuano A; Scavone C; Rafaniello C; Arcieri R; Rossi F; Panei P
Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S69-78. PubMed ID: 25171160
[TBL] [Abstract][Full Text] [Related]
31. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies.
Fredriksen M; Halmøy A; Faraone SV; Haavik J
Eur Neuropsychopharmacol; 2013 Jun; 23(6):508-27. PubMed ID: 22917983
[TBL] [Abstract][Full Text] [Related]
32. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
[TBL] [Abstract][Full Text] [Related]
33. The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research.
Savill NC; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill D
CNS Drugs; 2015 Feb; 29(2):131-51. PubMed ID: 25698145
[TBL] [Abstract][Full Text] [Related]
34. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
Hong J; Dilla T; Arellano J
BMC Psychiatry; 2009 Apr; 9():15. PubMed ID: 19366449
[TBL] [Abstract][Full Text] [Related]
35. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
36. Lower IQ is associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.
Mazzone L; Reale L; Mannino V; Cocuzza M; Vitiello B
CNS Drugs; 2011 Jun; 25(6):503-9. PubMed ID: 21649450
[TBL] [Abstract][Full Text] [Related]
37. Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder.
Hirata Y; Goto T; Takita Y; Trzepacz PT; Allen AJ; Ichikawa H; Takahashi M
Asia Pac Psychiatry; 2014 Sep; 6(3):292-301. PubMed ID: 24376099
[TBL] [Abstract][Full Text] [Related]
38. Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
Wietecha LA; Williams DW; Herbert M; Melmed RD; Greenbaum M; Schuh K
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):719-30. PubMed ID: 20035590
[TBL] [Abstract][Full Text] [Related]
39. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Prasad S; Harpin V; Poole L; Zeitlin H; Jamdar S; Puvanendran K;
Curr Med Res Opin; 2007 Feb; 23(2):379-94. PubMed ID: 17288692
[TBL] [Abstract][Full Text] [Related]
40. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.
Michelson D; Faries D; Wernicke J; Kelsey D; Kendrick K; Sallee FR; Spencer T;
Pediatrics; 2001 Nov; 108(5):E83. PubMed ID: 11694667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
